This narrative review summarizes the evidence supporting the use of foundational pharmacotherapies (ACEi, beta-blockers, ARBs, aldosterone blockers) for systolic heart failure.
Heart failure is an important cause of morbidity and mortality. Clinical trials over the past 2 decades have revolutionized the care of patients with systolic heart failure, and substantial data support the use of angiotensin-converting enzyme inhibitors, β-blockers, angiotensin-receptor blockers, and aldosterone blockers in the management of this serious condition. This article reviews the evidence on the pharmacologic treatment of heart failure, with a focus on recent clinical trials.
Yan et al. (Tue,) studied this question.